Trustmark National Bank Trust Department’s Vertex Pharmaceuticals VRTX Stock Holding History

Trustmark National Bank Trust Department's VRTX Position: Q2 2026 in Review

Trustmark National Bank Trust Department reduced its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, selling an estimated $74.5K and leaving 4,021 shares worth $2M. The position accounts for 0.12% of the portfolio, ranked #120.

Trustmark National Bank Trust Department first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.01M in Q3 2024. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

• Trustmark National Bank Trust Department held 4,021 shares of Vertex Pharmaceuticals worth $2M as of Q2 2026.
• Trustmark National Bank Trust Department sold 168 Vertex Pharmaceuticals shares in Q2 2026, an estimated $74.5K.
• Vertex Pharmaceuticals made up 0.12% of Trustmark National Bank Trust Department's portfolio in Q2 2026, its #120 holding.
• Trustmark National Bank Trust Department first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
• Trustmark National Bank Trust Department's Vertex Pharmaceuticals position peaked at $3.01M in Q3 2024.
• 1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trustmark National Bank Trust Department's 13F filing for Q2 2026, filed 12 Aug 2026.